Molecular Oncology

Mind the gap: Precision medicine shortcomings in NSCLC

HemOnc Today, July 10, 2019
Howard (Jack) West, MD
This year’s ASCO Annual Meeting included several major successes that should translate to new molecular targets in advanced non-small cell lung…
Point/Counter

Should lenvatinib be used as first-line therapy for slowly progressing radioiodine-refractory thyroid carcinoma?

HemOnc Today, July 10, 2019
POINT Lenvatinib is my preference as a first-line therapy when patients need treatment beyond levothyroxine and thyroid-stimulating hormone suppression.
Cover Story

New treatments, new outcomes for refractory thyroid cancer

HemOnc Today, July 10, 2019
Thyroid cancer diagnoses are increasing rapidly in the United States. But, with an estimated incidence of four cases per million population, thyroid…
Feature

Natural Killer Cell Therapy: A Look Inside a ‘Living Drug in a Bottle’

July 9, 2019
The ability to harness the human immune system and use it to fight cancer remains a significant area of focused research and is likely to remain so…
In the JournalsPerspective

Despite ‘incremental’ progress, long-term survival rates ‘have not budged’ in glioblastoma

July 8, 2019
Although median and short-term OS rates have improved for glioblastoma, still only a small proportion of patients achieve 5-year survival, according…

Therapeutic vaccine could improve checkpoint blockade efficacy for patients with cancer

July 3, 2019
Researchers at Icahn School of Medicine at Mount Sinai have developed a novel vaccine that uses immune stimulants to inhibit cancer cell growth among…
Meeting NewsVideo

VIDEO: Eribulin plus pembrolizumab shows no clinical benefit in breast cancer subtype

July 2, 2019
CHICAGO — The addition of pembrolizumab to eribulin demonstrated no significant improvements in terms of PFS, OS or objective response rate…
Meeting News

Guest Commentary: Frontline pembrolizumab noninferior to chemotherapy in certain GI cancers

June 29, 2019
In this Guest Commentary, Diana L. Hanna, MD, assistant professor of clinical medicine at the University of Southern
Meeting News

Guest Commentary: ‘Intriguing’ ASCO data highlights new excitement in colorectal cancer

June 27, 2019
In this Guest Commentary, HemOnc Today Next Gen Innovator Van Morris, MD, medical oncologist in the department of gastrointestinal medical
Advanced Practice

Understanding affected anatomy, physiology essential to management of taste disorders

HemOnc Today, June 25, 2019
David L. Jennings II, MSN, RN, AGPCNP-BC
Editor’s note:HemOnc Today’s regular columns for advanced practice providers (APPs) tackle common issues APPs face, discuss day-to-day